TLX Long entry. Telix Pharmaceuticals
Updated
Telix pharmaceuticals is revolutionizing the way the world detects and treats cancer, it's ahead of schedule and is kicking goals left right and centre.
very exciting prospects for this one, was able to cover massive bullish ground pre-2019 during the XJO, XAO Australian All Ordinaries (and world wide indices) bearish turn.
Now sitting in what looks like the final stages of WAVE 2 preparing for a (in my opinion) big bullish 3rd wave.
Target Entry: 0.65 - 0.63
Target Exits: $1.35, $1.80, $2.85
*note this is advice only and you should do you own fundamentals and technicals before entering a trade.
ATTACHED is a link to a very interesting release from TELIX pharmaceuticals
asx.com.au/asxpdf/20190109/pdf/441rj96tcb17hj.pdf
very exciting prospects for this one, was able to cover massive bullish ground pre-2019 during the XJO, XAO Australian All Ordinaries (and world wide indices) bearish turn.
Now sitting in what looks like the final stages of WAVE 2 preparing for a (in my opinion) big bullish 3rd wave.
Target Entry: 0.65 - 0.63
Target Exits: $1.35, $1.80, $2.85
*note this is advice only and you should do you own fundamentals and technicals before entering a trade.
ATTACHED is a link to a very interesting release from TELIX pharmaceuticals
asx.com.au/asxpdf/20190109/pdf/441rj96tcb17hj.pdf
Note
she is shaping up...
Note
In my view we are about to have our completed WAVE C down which should take us to our target. still aim for <0.63 how ever orders will be feathered in .65 .64 .63 .62
Note
we are edging ever so closely!! how exciting
Note
entry 1 has been hit
bullish indications coming in now
i think a quick slip further down is probable however any price here is good
0.63 - 0.66
Trade closed: target reached
i scaled out:1/4 $1.27
1/4
1/4
Note
1/4 $1.291/4 $1.33
1/4 $1.55
Note
I will be looking to get back in if economy holds at the $1 area
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.